Staff profile - Delphine Denoyer
Dr Delphine Denoyer
|Position:||Associate Research Fellow|
|Faculty or Division:||Faculty of Science Engineering & Built Environment|
|Department:||School of Life and Environmental Sciences|
|Campus:||Melbourne Burwood Campus|
Dr Delphine Denoyer is a research fellow in the Centre for Cellular and Molecular Biology at Deakin University. She obtained her PhD in Biomedical Engineering in France in 2004, where she investigated the mechanisms of uptake of new radiopharmaceuticals in cancer cells. After being awarded a prestigious fellowship from NHMRC/INSERM (Australia/France research cooperation program), she relocated to Australia in 2007 to pursue her interest in preclinical validation of radiopharmaceuticals for imaging and therapy of cancers at the Peter MacCallum Cancer Centre, Melbourne. In November 2013, she joined the Metals in Medicine Laboratory. Her research focus moved to the metallomics field where she uses her expertise in translational research to investigate the role of copper in the development and growth of prostate cancer.
Cancer Biology (in particular melanoma, prostate and breast cancers)
Preclinical validation of new compounds for imaging and therapy of cancer
PET/SPECT imaging, autoradiography
Refereed journal articles (last 5 years only)
1. Denoyer D, et al. Heterogeneous Copper Concentrations in Cancerous Human Prostate Tissues. Prostate 2015 May 27. doi: 10.1002/pros.23022.
2. Roberts MP, et al. Synthesis and in Vivo Evaluation of [(123)I]Melanin-Targeted Agents. J Med Chem. 2015 Aug 13;58(15):6214-24. doi: 10.1021/acs.jmedchem.5b00777.
3. Denoyer D, et al. Analysis of 177Lu-octreotate therapy-induced DNA damage in peripheral blood lymphocytes of patients with neuroendocrine tumours. J Nucl Med 2015 Apr;56(4):505-511.
4. Carter RZ, et al. Tumour but not stromal expression of β3 integrin is essential, and is required early, for spontaneous dissemination of bone-metastatic breast cancer. J Pathol. 2014 Nov 28.doi: 10.1002/path.4490.
5. Devaud C, et al. Foxp3 expression in macrophages associated with RENCA tumors in mice. PLoS One 2014 Sep 29;9(9):e108670. doi:10.1371/journal.pone.0108670.
6. Denoyer D, et al. Bone-derived soluble factors and laminin-511 cooperate to promote migration, invasion and survival of bone-metastatic breast tumor cells. Growth Factors 2014 Apr;32(2):63-73.
7. Al-Ejeh F, et al. Postchemotherapy and Tumor-Selective Targeting with the La-Specific DAB4 Monoclonal Antibody Relates to Apoptotic Cell Clearance. J Nucl Med 2014 May;55(5):772-779.
8. Paterson B, Roselt P, Denoyer D, et al. PET imaging of tumours with a 64Cu-labeled macrobicyclic cage amine ligand tethered to Tyr 3-octreotate. Dalton Transactions 2014 Jan;43(3):1386-1396.
9. Lobachevsky P, Smith J, Denoyer D, et al. Tumour targeting of Auger emitters using DNA ligands conjugated to octreotate. Int J Radiat Biol 2012 Dec;88(12):1009-18.
10. Malaterre J, McPherson CS, Denoyer D, et al. Enhanced Lithium Induced Brain Recovery Following Cranial Irradiation is not impeded by inflammation. Stem Cells Transl Med. 2012 Jun;1(6):469-79.
11. Denoyer D, et al. Preclinical characterization of (18)F-D-FPHCys, a new amino acid-based PET tracer. Eur J Nucl Med Mol Imaging. 2012 Apr;39(4):703-12.
12. Kusuma N*, Denoyer D*, et al. Integrin-dependent response to laminin-511 regulates breast tumor cell invasion and metastasis. Int J Cancer. 2012 Feb 1;130(3):555-66. *Co-first author.
13. Ma MT, Neels OC, Denoyer D, et al. Gallium-68 complex of a macrobicyclic cage amine chelator tethered to two integrin-targeting peptides for diagnostic tumor imaging. Bioconjug Chem. 2011 Oct 19;22(10):2093-103.
14. Bourdier T, Shepherd R, Berghofer P, Jackson T, Fookes CJR, Denoyer D, et al. Radiosynthesis and Biological Evaluation of L and D S-(3-[18F]Fluoropropyl)-homocysteine for Tumor Imaging using Positron Emission Tomography. J Med Chem. 2011 Mar 24;54(6):1860-70.
15. Denoyer D, Potdevin T, Roselt P, Neels OC, Kirby L, Greguric I, Katsifis A, Dorow DS, Hicks RJ. Improved detection of regional melanoma metastasis using [18F]-MEL050, a melanin specific PET probe, by peri-lesional administration. J Nucl Med. 2011 Jan;52:115-122.
Reviews/Editorial (last 5 years only)
1. Denoyer D, et al. Targeting copper in cancer therapy: ‘Copper That Cancer’. Metallomics, 2015, DOI: 10.1039/C5MT00149H.
2. Denoyer D and Pouliot N. Radionuclide theranostics in cancer. Journal of Molecular Imaging and Dynamics 2014 In press.
3. Pouliot N and Denoyer D. Molecular imaging of metabolism in cancer metastasis. Cancer Forum 2014 August;38(2):124-128.